Shoshana Frankenburg

Jerusalem, JM, Israel

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Alternative splicing of modulatory immune receptors in T lymphocytes: a newly identified and targetable mechanism for anticancer immunotherapy.

Alternative splicing of modulatory immune receptors in T lymphocytes: a newly identified and targetable mechanism for anticancer immunotherapy.

Journal: Frontiers in immunology
Published: September 02, 2024

The future of affordable cancer immunotherapy.

The future of affordable cancer immunotherapy.

Journal: Frontiers in immunology
Published: June 27, 2023

Preventing skin toxicities induced by EGFR inhibitors by topically blocking drug-receptor interactions.

Preventing skin toxicities induced by EGFR inhibitors by topically blocking drug-receptor interactions.

Journal: Science translational medicine
Published: June 07, 2023

The role of immune checkpoint receptors in the malignant phenotype of cutaneous T cell lymphoma.

The role of immune checkpoint receptors in the malignant phenotype of cutaneous T cell lymphoma.

Journal: Immunologic research
Published: February 28, 2022

Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions.

Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions.

Journal: Cancer immunology research
Published: September 21, 2020

SLAMF6​ deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint.

SLAMF6​ deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint.

Journal: eLife
Published: October 07, 2019

Soluble SLAMF6 Receptor Induces Strong CD8+ T-cell Effector Function and Improves Anti-Melanoma Activity In Vivo.

Soluble SLAMF6 Receptor Induces Strong CD8+ T-cell Effector Function and Improves Anti-Melanoma Activity In Vivo.

Journal: Cancer immunology research
Published: July 22, 2017

Phenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanoma.

Phenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanoma.

Journal: MedChemComm
Published: July 04, 2017

Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBL.

Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBL.

Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)
Published: August 27, 2016

Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade.

Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade.

Journal: Journal of immunology research
Published: January 11, 2016

Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells.

Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells.

Journal: Clinical and experimental immunology
Published: July 21, 2015

Human T cell crosstalk is induced by tumor membrane transfer.

Human T cell crosstalk is induced by tumor membrane transfer.

Journal: PloS one
Published: September 14, 2014
Showing 1-12 of 14

Last Updated: 09/26/2026